Article ID Journal Published Year Pages File Type
8690417 Pediatric Neurology 2018 6 Pages PDF
Abstract
These results demonstrate similar abobotulinumtoxinA efficacy and safety profiles in children with spasticity who are new to botulinum toxin treatment and those children who were previously treated. The efficacy and safety of abobotulinumtoxinA treatment in these previously treated patients were comparable with the overall trial population, indicating that doses of 10 and 15 U/kg/leg are suitable starting doses for children with spasticity regardless of the previous botulinum toxin preparation used.
Related Topics
Life Sciences Neuroscience Developmental Neuroscience
Authors
, , , , , ,